Jennifer Keiser
16
0
0
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 16 trials
100.0%
+13.5% vs industry average
31%
5 trials in Phase 3/4
64%
9 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini
Role: lead
Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita
Role: lead
Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
Role: lead
Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
Role: lead
Efficacy and Safety of Oxantel Pamoate in Children Infected With Trichuris Trichiura
Role: lead
Co-administration of IVM and ALB in School-based Deworming in Uganda
Role: lead
Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Role: lead
Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
Role: lead
Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura
Role: lead
Efficacy and Safety of IVM/ALB Co-administration
Role: lead
Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Role: lead
Efficacy and Safety of MOX/ALB Co-administration
Role: lead
Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm
Role: lead
Albendazole Dose Finding and Pharmacokinetics in Children and Adults
Role: lead
Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm
Role: lead
Efficacy and Safety of a Multi-dose Regimen of Mebendazole Against Hookworm in Children
Role: lead
All 16 trials loaded